Ewing’s sarcoma presents a unique opportunity to develop tumor specific targeted therapy due to a pathognomonic chromosomal translocation. Proper function of EWS-FLI1, protein product of this chromosomal translocation, is required for tumor cell survival. We will develop a cell-based High Throughput Screening assay. We will generate Ewing’s cell-lines expressing two fluorescent proteins. GFP will be expressed from an EWS-FLI1 regulated promoter and RFP from an unrelated negative control promoter. In this dual color HTS assay, a small molecule library will be screened for inhibiting GFP but not RFP, which will provide lead compounds for novel Ewing’s sarcoma therapies.
Aykut Üren, MD,
Lombardi Comprehensive Cancer Center, Georgetown University
Recipient of the: $25,000 Marny S. Tobin Memorial Research Award